Cell cycle analysis of normal, atrophic, and hyperplastic breast epithelium using two-color multiparametric flow cytometry.
Abstract
We performed two-color flow cytometric synthesis phase fraction (SPF) determinations on cytokeratin-labeled benign epithelial populations from 142 breast specimens (41 mastectomy, 70 diagnostic biopsy, 31 reduction mammoplasty). There was wide variability of SPF, ranging from 0.1 to 3.5%, with a frequency distribution skewed to higher values (mean 0.75%, median 0.5%). The mean SPE for women less than 29 years was 0.91%, vs. 0.89% for 30-42 years, 0.66% for 43-49 years, and 0.56% for > or = 50 years (P = 0.05). Histologically atrophic tissue samples exhibited a mean SPF approximately half that of morphologically normal tissue from premenopausal age women (0.79% vs. 0.36%, P = 0.02). Tissues showing histologically proliferative fibrocystic features had a greater mean SPF than non-proliferative fibrocystic tissues (0.59% vs. 0.92%); however, due to the wide spread of values within each of these categories, this difference was not statistically significant and neither group was significantly different from 'normal' tissue samples. Patients with histologically normal breast tissue, though, were significantly younger (mean = 34.6 years) than those with fibrocystic changes (non-proliferative mean = 53.4 years vs. proliferative mean = 42.8 years, P = 0.005). Synchronous right- and left-sided specimens obtained from reduction mammoplasty demonstrated significantly correlated SPF determinations (R = 0.77). We conclude that selective analysis of epithelial populations using two-color flow cytometry provides cell cycle information in benign breast tissue which is analogous to that obtained by labor-intensive nucleotide labeling studies. This study also confirms the biologic variability and age-dependence of breast epithelial proliferation. Finally, the data imply that derangements of cell proliferation in fibrocystic conditions are heterogeneous, complex and incompletely correlated with histologic parameters such as hyperplasia.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | breast
|
유방 | dict | 5 | |
| 시술 | reduction mammoplasty
|
유방성형술 | dict | 2 | |
| 해부 | Cell
|
scispacy | 1 | ||
| 해부 | tissue
|
scispacy | 1 | ||
| 해부 | premenopausal
|
scispacy | 1 | ||
| 해부 | fibrocystic tissues
|
scispacy | 1 | ||
| 해부 | breast tissue
|
scispacy | 1 | ||
| 합병증 | hyperplasia
|
scispacy | 1 | ||
| 약물 | SPE
|
C0764874
SpeA protein, Streptococcus pyogenes
|
scispacy | 1 | |
| 약물 | nucleotide
|
C0028630
Nucleotides
|
scispacy | 1 | |
| 질환 | fibrocystic
|
C1418605
PKHD1 gene
|
scispacy | 1 | |
| 질환 | non-proliferative fibrocystic
|
C1332628
Breast Fibrocystic Change, Non-Proliferative Type
|
scispacy | 1 | |
| 질환 | non-proliferative
|
scispacy | 1 | ||
| 질환 | hyperplasia
|
C0020507
Hyperplasia
|
scispacy | 1 | |
| 질환 | hyperplastic breast epithelium
|
scispacy | 1 | ||
| 질환 | cytokeratin-labeled benign epithelial populations
|
scispacy | 1 | ||
| 질환 | breast specimens
|
scispacy | 1 | ||
| 질환 | tissue samples
|
scispacy | 1 | ||
| 질환 | epithelial populations
|
scispacy | 1 | ||
| 질환 | benign breast tissue
|
scispacy | 1 | ||
| 질환 | breast epithelial
|
scispacy | 1 | ||
| 기타 | women
|
scispacy | 1 | ||
| 기타 | Patients
|
scispacy | 1 | ||
| 기타 | SPF
→ synthesis phase fraction
|
scispacy | 1 |
MeSH Terms
Adult; Age Factors; Breast; Cell Cycle; Cell Division; DNA; Epithelium; Female; Fibrocystic Breast Disease; Flow Cytometry; Humans; Hyperplasia; Middle Aged
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.
- Implant-based versus autologous mastopexy after massive weight loss: Complications and patient satisfaction.